Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01207388 · OUTCOME

Resource Utilization: Number of Participants Reporting Use of Transfusion of Blood Products

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) · Source last updated 2020-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months

Analysis population: Full analysis set

Groups in this outcome

Blinatumomab

Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Blinatumomab116

Reported measurements

Overall
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Blinatumomab14Not reportedNot reportedNot reportedNot reported
Cycle 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Blinatumomab5Not reportedNot reportedNot reportedNot reported
Cycle 2
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Blinatumomab8Not reportedNot reportedNot reportedNot reported
Cycle 3
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Blinatumomab0Not reportedNot reportedNot reportedNot reported
Cycle 4
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Blinatumomab1Not reportedNot reportedNot reportedNot reported
Follow-up period
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Blinatumomab0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        14
    title
    Overall
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        5
    title
    Cycle 1
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        8
    title
    Cycle 2
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Cycle 3
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Cycle 4
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Follow-up period
denoms
  1. counts
    1. group Id
      OG000
      value
      116
    units
    Participants
groups
  1. description
    Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
    id
    OG000
    title
    Blinatumomab
param Type
COUNT_OF_PARTICIPANTS
population Description
Full analysis set
reporting Status
POSTED
time Frame
From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months
title
Resource Utilization: Number of Participants Reporting Use of Transfusion of Blood Products
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice